Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, has appointment Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017.
Ex Janssen’s Manufacturing and Technical Operations Vice President will be responsible for manufacturing, supply chain, QA and project management in Kiadis Pharma.
Arthur Lahr, CEO designate of Kiadis Pharma, said: “I am confident that Jan will ensure the smooth running of our Phase III operations and will successfully set up and run our commercial supply chain.”
Commenting on his appointment Jan Feijen said: “With the Company’s pivotal Phase III trial with ATIR101 now underway, it is vital that the necessary steps are taken to ensure everything continues to run smoothly and that we have all logistics in hand ready to roll out commercially in the future.”